Does Semaglutide Increase Risk of a Rare Eye Condition (NAION)? Large-Scale Analysis
Large-scale analysis investigated the potential association between semaglutide/GLP-1 drugs and non-arteritic anterior ischemic optic neuropathy (NAION), addressing safety concerns about a rare eye condition.
Quick Facts
What This Study Found
Study evaluated the association between semaglutide/GLP-1 RA use and NAION risk using large-scale clinical data, addressing a flagged safety signal for this rare eye condition.
Key Numbers
Patients aged 12 and older were included. The study used the TriNetX network, which covers millions of U.S. health records. Exact event rates not detailed in available abstract.
How They Did This
Large-scale analysis of clinical data examining the association between GLP-1 receptor agonist use and NAION incidence in patients with T2DM and/or obesity.
Why This Research Matters
NAION can cause permanent vision loss. With millions taking GLP-1 drugs, even a small increase in NAION risk would affect thousands of people. Clarifying this safety signal is critical.
The Bigger Picture
As GLP-1 drugs become among the most prescribed medications worldwide, post-marketing safety surveillance for rare events becomes increasingly important. NAION is very rare (~2-10 per 100,000), making large datasets essential for detecting any meaningful risk change.
What This Study Doesn't Tell Us
NAION is extremely rare, limiting statistical power even in large datasets. Diabetes and obesity themselves are NAION risk factors, confounding the analysis. Observational data cannot prove causation.
Questions This Raises
- ?Is the NAION signal specific to semaglutide or shared across all GLP-1 drugs?
- ?Does rapid weight loss itself contribute to NAION risk regardless of drug used?
- ?Should patients with pre-existing optic nerve conditions avoid GLP-1 drugs?
Trust & Context
- Key Stat:
- NAION risk assessed Large-scale analysis of the potential association between GLP-1 drugs and a rare optic nerve condition causing sudden vision loss
- Evidence Grade:
- Moderate evidence: large-scale observational analysis of a rare event, with inherent limitations of confounding and statistical power.
- Study Age:
- Published in 2025. Addresses an active safety investigation for GLP-1 drugs.
- Original Title:
- The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy.
- Published In:
- American journal of ophthalmology, 274, 24-31 (2025)
- Authors:
- Abbass, Nadia J, Nahlawi, Raya, Shaia, Jacqueline K, Allan, Kevin C, Kaelber, David C, Talcott, Katherine E, Singh, Rishi P
- Database ID:
- RPEP-09727
Evidence Hierarchy
Frequently Asked Questions
Can semaglutide cause vision problems?
NAION (sudden vision loss from optic nerve blood flow blockage) has been flagged as a potential concern. This large-scale analysis evaluated the evidence. NAION is very rare, and diabetes itself is a risk factor. Any sudden vision change should be reported to your doctor.
Should I stop my GLP-1 drug because of NAION concerns?
Do not stop medication without consulting your doctor. NAION is extremely rare, and the benefits of GLP-1 drugs for diabetes and obesity management are well-established. Discuss any concerns with your prescriber.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09727APA
Abbass, Nadia J; Nahlawi, Raya; Shaia, Jacqueline K; Allan, Kevin C; Kaelber, David C; Talcott, Katherine E; Singh, Rishi P. (2025). The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy.. American journal of ophthalmology, 274, 24-31. https://doi.org/10.1016/j.ajo.2025.02.025
MLA
Abbass, Nadia J, et al. "The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy.." American journal of ophthalmology, 2025. https://doi.org/10.1016/j.ajo.2025.02.025
RethinkPeptides
RethinkPeptides Research Database. "The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteri..." RPEP-09727. Retrieved from https://rethinkpeptides.com/research/abbass-2025-the-effect-of-semaglutide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.